Novo Nordisk Research Center Indianapolis, Inc. (NNRCI) was established in late 2015 when Novo Nordisk acquired Calibrium and MB2, two private companies co-founded by Dr. Richard DiMarchi that were focused on developing protein-based products for diabetes and obesity. NNRCI is in the early stages of founding an elite research team to further the success of Dr. DiMarchi’s work in union with Novo Nordisk’s global research efforts.
NNRCI is focused on early discovery projects within the diabetes and obesity areas. Our scientists apply cutting edge technologies to bring molecules to market. Right now, that means identifying protein-based therapies for obesity and prevention of diabetes, and diabetes treatment.